Beta Drugs Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on February 04, 2026
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beta Drugs Limited has called an Extraordinary General Meeting on February 4, 2026, to seek shareholder approval on four key items. First, the company proposes to increase its authorised share capital from ₹11 crore to ₹11.40 crore (1.10 crore to 1.14 crore equity shares of ₹10 each). Second, it seeks approval for the 'Beta Drugs Limited Employee Stock Option Plan 2026' (ESOP 2026), covering up to 2,00,000 stock options (1.98% of paid-up equity shares) for employees. Third, it wants to extend ESOP 2026 benefits to employees of group, holding, subsidiary, and associate companies. Fourth, it proposes a preferential issue of 2,83,668 equity shares at ₹1,712.49 per share (₹1,702.49 premium) to specific allottees, as part of a share-swap deal where these allottees will transfer their shares in Nivian Lifesciences Private Limited to Beta Drugs in exchange for Beta Drugs' shares, valued at approximately ₹48.58 crore in total.
Shareholders should review these proposals carefully as they involve equity dilution through the ESOP and a preferential share-swap issuance, which will expand the share base. The share swap signals a potential acquisition or strategic investment in Nivian Lifesciences Private Limited. Investors should evaluate the implied valuation of Nivian Lifesciences shares and the dilution impact on existing holdings.